INCANNEX HEALTHCARE Inactive Instrument
Incannex Healthcare Stock Australian S.E.
Equities
IHL
AU000000IHL8
Pharmaceuticals
| Sales 2022 | 782K 502K | Sales 2023 | 1.01M 651K | Capitalization | 4.37B 2.81B |
|---|---|---|---|---|---|
| Net income 2022 | -14M -8.99M | Net income 2023 | -20M -12.84M | EV / Sales 2022 | 9,113 x |
| Net cash position 2022 | 37.5M 24.08M | Net cash position 2023 | 32.58M 20.92M | EV / Sales 2023 | 4,281 x |
| P/E ratio 2022 |
-447
x | P/E ratio 2023 |
-212
x | Employees | 3 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 78.46% |
More Fundamentals
* Assessed data
More news
More press releases
Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Companyâs diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.
Sector
Pharmaceuticals
Calendar
2024-08-27
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +40.29% | 6.02B | |
| -15.73% | 4.55B | |
| -9.40% | 3.13B | |
| -1.60% | 3.07B | |
| -1.23% | 2.57B | |
| +34.89% | 1.82B | |
| -11.37% | 1.63B | |
| -5.02% | 1.57B | |
| -13.21% | 1.54B |
